Integrated 6-base cfDNA profiling reveals complementary genetic, epigenetic and fragmentomic biomarkers, enabling the selection of the most powerful biomarker combinations for cancer detection

Cell-free DNA (cfDNA) contains complementary genetic, epigenetic and fragmentomic signals that can inform cancer detection. However, these biomarkers are typically measured using separate assays, increasing sample input requirements, analytical complexity, and inter-assay variability.